iBio Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Significant Transactions (Details)

Significant Transactions (Details)					3 Months Ended	12 Months Ended
Significant Transactions (Details)	Jan. 01, 2023 item	Sep. 16, 2022 USD ($) lease shares	Nov. 01, 2021 USD ($) $ / shares shares	Aug. 23, 2021 USD ($) shares	Dec. 31, 2022 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Value of shares purchased in transaction							$ 650,000
General and administrative expenses						$ 11,674,000	$ 19,016,000
RubrYc Therapeutics
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of equipment leases assumed in asset acquisition		3
The Purchase and Sale Agreement \| College Station Investors
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from sale of building			$ 28,000,000
Purchase price for Ground Lease Property			28,750,000
Base rent expense			$ 151,450
Interest rate on lease (percentage of facility's market value)			6.50%
The Credit Agreement \| Woodforest National Bank
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Secured term loan			$ 22,375,000
The Warrant \| Bryan Capital \| Common Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants, shares issued \| shares			2,579
Exercise price per share of warrants \| $ / shares			$ 665
Warrants issued and exercisable \| shares			579
Value of exercisable warrants			$ 217,255
Collaboration, Option and License Agreement \| RubrYc Therapeutics
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration and license agreement, agreement term				5 years
Collaboration and license agreement, royalty payment term				10 years
Stock Purchase Agreement \| RubrYc Therapeutics \| Series A-2 Preferred Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares purchased in transaction \| shares				2,864,345
Value of shares purchased in transaction				$ 7,500,000
Asset Purchase Agreement \| RubrYc Therapeutics
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Liability for contingent consideration		$ 5,000,000
Cash advances to RubrYc to support operations		484,000
Transaction costs		$ 208,000
Impairment of investment in RubrYc								$ 1,760,000
Impairment of current prepaid expense								288,000
Impairment of noncurrent prepaid expense								$ 864,000
Number of equipment leases assumed in asset acquisition \| lease		3
Finance leases		$ 814,000
Asset Purchase Agreement \| RubrYc Therapeutics \| Common Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares issued per agreement \| shares		5,117
Fair value of shares issued in agreement		$ 1,000,000
Fair value of shares issued and subject to lockup period		$ 650,000
Separation Agreement and General Release \| Dr. Martin Brenner, Chief Executive Officer
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Period of bi-monthly installments of current base salary	24 months
Period of bi-monthly installments of target bonus	24 months
Maximum period for coverage of health insurance	18 months
COBRA subsidy period	18 months
Lump sum payment equal to six time the COBRA subsidy \| item	6
General and administrative expenses					$ 2,130,000
Accrued expenses						$ 500,000